News - Esbriet


Current filters:


Popular Filters

Ireland's HSE to reimburse InterMune's Esbriet for IPF


US biotech firm InterMune's (Nasdaq: ITMN) UK subsidiary says that Ireland's Health Service Executive…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

Pricing and reimbursement conditions for InterMune's Esbriet in Italy


US biotech firm InterMune (Nasdaq: ITMN) says that the board of the Italian Drug Agency (AIFA) has approved…

BiotechnologyEsbrietEuropeInterMunePricingRespiratory and Pulmonary

New idiopathic pulmonary fibrosis treatment may open up valuable research opportunity, says GlobalData


Further research is a prerequisite to shine a light on idiopathic pulmonary fibrosis (IPF) and offer…

BiotechnologyEsbrietInterMunePricingRare diseasesRegulationResearch

Positive NICE news for GSK's Revolade and InterMune's Esbriet


UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

UK pharma group slams NICE for failing to recognize nature of discovery and development


The Association of the British Pharmaceutical Industry (ABPI) yesterday expressed major concern on behalf…


UK's NICE initially negative on InterMune's Esbriet for idiopathic pulmonary fibrosis


UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) said yesterday that…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

French price regulator authorizes reimbursement of InterMune's Esbriet


USA-based InterMune (Nasdaq: ITMN) says that French regulator the Comite Economique des Produits de…

EsbrietEuropeInterMunePharmaceuticalPricingRespiratory and Pulmonary

InterMune to divest Actimmune for $55 million; to focus on Esbriet


California, USA-based biotech firm InterMune (Nasdaq: ITMN) says that it has reached a definitive agreement…

ActimmuneBiotechnologyEsbrietFinancialImmunologicalsInterMuneMergers & AcquisitionsRespiratory and PulmonaryVidara Therapeutics

French Transparency Commission issues favorable opinion on Esbriet


There was good news last week for USA-based InterMune (Nasdaq: ITMN) when the Transparency Commission…

EsbrietEuropeInterMunePharmaceuticalPricingRegulationRespiratory and Pulmonary

Esbriet offers additional benefit, says German G-BA


USA-based InterMune (Nasdaq: ITMN) says that the German Federal Joint Committee (G-BA) has announced…

EsbrietEuropeInterMunePharmaceuticalPricingRegulationRespiratory and Pulmonary

Germany’s IQWIG negative on InterMune’s Esbriet


US biotech firm InterMune (Nasdaq: ITMN) says that Germany’s private Institute for Quality and Efficiency…

BiotechnologyEsbrietEuropeInterMuneRare diseasesRegulationRespiratory and Pulmonary

InterMune’s IPF drug Esbriet sees first European launch, in Germany


US biotech firm InterMune (Nasdaq: ITMN) has announced that Esbriet (pirfenidone) will be offered to…

BiotechnologyEsbrietEuropeInterMuneMarkets & MarketingPharmaceuticalRespiratory and Pulmonary

Back to top